New 'Immune Mobilizer' drug enters human trials for Tough-to-Treat cancers
Disease control
Ongoing
This study is testing a new type of cancer drug called brenetafusp (IMC-F106C) in adults with advanced solid tumors that have a specific marker called PRAME. The first part of the study aims to find a safe and effective dose, and the second part will see how well the drug works t…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC